SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with ...
Hosted on MSN1mon
Impactful tropical threat could be brewing in Caribbean with potential track into Gulf of MexicoThe growing concern is linked to a phenomenon known as the Central American Gyre, which has historically contributed to tropical storm formation in the Caribbean or Gulf of Mexico in the early ...
In trading on Friday, shares of Gyre Therapeutics Inc (Symbol: GYRE) crossed above their 200 day moving average of $14.43, changing hands as high as $14.83 per share. Gyre Therapeutics Inc shares ...
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback